IPCIF Stock - Intellipharmaceutics International Inc.
Unlock GoAI Insights for IPCIF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $65,728 | $65,728 | $1.40M | $1.40M | $1.71M |
| Gross Profit | $65,728 | $-190,726 | $970,580 | $1.37M | $1.59M |
| Gross Margin | 100.0% | -290.2% | 69.3% | 97.6% | 92.7% |
| Operating Income | $-2,850,507 | $-2,850,507 | $-4,173,076 | $-4,678,308 | $-13,326,266 |
| Net Income | $-2,892,394 | $-2,892,394 | $-5,145,155 | $-3,390,965 | $-13,738,888 |
| Net Margin | -4400.6% | -4400.6% | -367.1% | -241.9% | -802.2% |
| EPS | $-0.09 | $-0.10 | $-0.22 | $-0.16 | $-2.88 |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Visit WebsiteEarnings History & Surprises
IPCIFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 28, 2024 | — | — | — | — |
Q4 2024 | Oct 24, 2024 | — | — | — | — |
Q2 2024 | Jun 17, 2024 | — | — | — | — |
Q2 2024 | Apr 15, 2024 | — | — | — | — |
Q4 2023 | Oct 16, 2023 | — | $-0.06 | — | — |
Q3 2023 | Sep 26, 2023 | — | $-0.00 | — | — |
Q3 2023 | Jul 14, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 30, 2022 | — | $-0.03 | — | — |
Q4 2022 | Oct 14, 2022 | — | $-0.01 | — | — |
Q3 2022 | Jul 21, 2022 | — | $-0.05 | — | — |
Q2 2022 | May 6, 2022 | — | $-0.08 | — | — |
Q2 2022 | Apr 14, 2022 | — | $-0.03 | — | — |
Q2 2022 | Apr 1, 2022 | — | $-0.06 | — | — |
Q4 2021 | Oct 15, 2021 | — | $-0.04 | — | — |
Q3 2021 | Jul 15, 2021 | — | $-0.04 | — | — |
Q2 2021 | Apr 14, 2021 | — | $-0.04 | — | — |
Q4 2020 | Oct 15, 2020 | — | $0.04 | — | — |
Q3 2020 | Jul 15, 2020 | — | $-0.04 | — | — |
Q1 2020 | Mar 30, 2020 | — | $-0.06 | — | — |
Q1 2020 | Feb 28, 2020 | — | $-0.04 | — | — |
Latest News
Frequently Asked Questions about IPCIF
What is IPCIF's current stock price?
What is the analyst price target for IPCIF?
What sector is Intellipharmaceutics International Inc. in?
What is IPCIF's market cap?
Does IPCIF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IPCIF for comparison